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Aim: Apoptosis is associated with various types of hepatic dis-
orders. We have developed a novel cell-transfer drug delivery
system (DDS) using a multifunctional envelope-type nano device
that targets liver sinusoidal endothelial cells (LSECs). The pur-
pose of this study was to determine the efﬁcacy of the novel
DDS containing siRNA at suppressing apoptosis in LSECs.
Methods: Bax siRNA was transfected into a sinusoidal endo-
thelial cell line (M1) to suppress apoptosis induced by an anti-
Fas antibody and staurosporine. C57BL/6J mice were divided
into three groups: (i) a control group, only intravenous saline;
(ii) a nonselective group, injections of siRNA sealed in the
nonselective DDS; and (iii) an LSEC-transfer efﬁcient group, injec-
tions of siRNA sealed in an LSEC-transfer efﬁcient DDS. Hepatic
cell apoptosis was induced by an anti-Fas antibody.
Results: Bax siRNA had an anti-apoptotic effect on M1 cells.
Serum alanine aminotransferase was reduced in the LSEC-transfer
efﬁcient group, as were cleaved caspase-3 and the number
of terminal deoxynucleotidyl transferase dUTP nick end labeling
positive hepatocytes. Silver impregnation staining indicated that
the sinusoidal space was maintained in the LSEC-transfer
efﬁcient group but not in the other groups. Electron microscopy
showed that the LSECs were slightly impaired, although the
sinusoidal structure was maintained in the LSEC-transfer efﬁcient
group.
Conclusion: Hepatocyte apoptosis was reduced by the efﬁ-
cient suppression of LSEC apoptosis with a novel DDS.
Protecting the sinusoidal structure by suppressing LSEC damage
will be an effective treatment for acute liver failure.
Key words: acute liver failure, apoptosis, Bax, drug delivery
system, liver sinusoidal endothelial cell, siRNA
INTRODUCTION
APOPTOSIS IN THE liver is associated with variousliver disorders, such as acute and chronic hepatitis
and viral hepatitis.1,2 In liver inﬂammation, liver sinusoi-
dal endothelial cells (LSECs) are considered to play impor-
tant roles in the migration of inﬂammatory cells into
hepatocytes and in the altered expression of adhesion
molecules.3–5
The suppression of apoptosis by siRNA prevents acute
liver failure.6–9 Pro-apoptotic factors, including Bax in the
mitochondrial apoptosis pathway, have been targeted by
siRNA.10,11 Bax siRNA can accumulate in the liver after
i.v. administration; however, the siRNA is not targeted
to either hepatocytes or LSECs. The mechanisms lead-
ing to acute liver failure and the roles of hepatocytes
and LSECs in apoptosis in the liver remain unknown.
In our previous study, hepatocytes were impaired fol-
lowing LSEC deterioration in an acute hepatitis model.12
The study suggested that LSECs play an important role in
apoptosis and that inhibiting LSEC damage diminishes
acute liver failure. However, the study only indicated that
LSEC damage occurred in the early phase of liver failure
before hepatocyte damage. Evaluating LSECs was difﬁcult
because there was no drug delivery system (DDS) that
efﬁciently targets LSECs.
Recently, we have developed a novel DDS, namely, a
multifunctional envelope-type nano device (MEND), that
accumulates effectively in LSECs.13,14 This DDS has per-
mitted the effective knockdown of target gene expression
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in LSECs by promoting the efﬁcient uptake of sealed siRNA
into LSECs.14
We hypothesized that suppressing LSEC apoptosis
would diminish acute liver failure more effectively than
suppressing hepatocyte apoptosis. In this study, we used
Bax siRNA to suppress apoptosis in the liver and injected
the novel DDS encapsulating Bax siRNA into mice with
anti-Fas antibody-induced acute liver damage. Our aim
was to examine the effects of suppressing LSEC apoptosis
and to elucidate the mechanism responsible for acute
liver damage.
METHODS
siRNA construction
INPRELIMINARY EXPERIMENTS, we examined Bax andBak gene expression levels in AML12 cells (CRL-2254;
American Type Culture Collection, Manassas, VA, USA),
which is a hepatocyte cell line inmice. Bak gene expression
in AML12 cells was below the limit of detection, indicating
that the expression of Bak in hepatocytes was extremely
low. Additionally, we administrated an anti-Fas antibody
(Jo-2; BD Pharmingen, San Diego, CA, USA) to mice and
measured Bax and Bak gene expressions. Bak expression
in total liver tissue did not increase after the administration
compared with before the administration. In contrast, Bax
expression increased. Therefore, the inhibition of Bax ex-
pression was expected to be effective to suppress apoptosis
in the liver. The use of Bax siRNA to knockdown Bax gene
expression has been previously reported.8 We purchased
Bax siRNA (5′-AGCGAGTGTCTCCGGCGAATT-3′) from
Hokkaido System Science (Sapporo, Japan).
In vitro experiments
Cell lines
M1 is a liver sinusoidal endothelial cell line created
from the isolation of non-parenchymal cells from a
H-2Kb-tsA58-transgenic mouse liver transfected with
the SV40 large T antigen gene.15 M1 cells were seeded
at conﬂuence and cultured in a humidiﬁed atmosphere
containing 5% CO2 at 37°C in ASF104N medium
(Ajinomoto Healthy Supply, Tokyo, Japan) containing
2% fetal bovine serum.
siRNA transfection and induction of apoptosis
Bax siRNA transfections were performed using Lipofecta-
mine RNAiMAX (Invitrogen Life Technologies, Gaithersburg,
MD, USA) and Opti-MEM (Invitrogen Life Technologies)
according to the manufacturer’s recommendations.16 M1
cells were grown to 60–70% conﬂuence in six-well plates
and then transfected with 75 pmol of siRNA per well. After
24 h, the cells in each dish were treated with 2.0 μg/mL
anti-Fas antibody or 0.1 μM staurosporine (STS)
(Sigma-Aldrich, Tokyo, Japan). The cells were divided
into two groups: (i) the Bax siRNA() group
(medium only); and (ii) the Bax siRNA(+) group
(siRNA transfection). Cell samples were taken at 0, 12
and 24 h after anti-Fas antibody administration and
at 0, 2 and 4 h after STS administration. For real-time
reverse transcription polymerase chain (RT–PCR)
analysis, the cells were harvested using the buffer from
an RNA kit (NucleoSpin RNA; Takara Bio, Otsu, Japan),
which isolates total cellular RNA. For western blot analysis,
the cells were washed with phosphate-buffered saline
(PBS), harvested using sodium dodecylsulfate (SDS) sam-
ple buffer and mixed with β-mercaptoethanol; the samples
were then centrifuged, and the supernatant was collected.
In vivo experiments
Animals
Eight- to nine-week-old female C57BL/6J mice (Charles
River Laboratories International, Yokohama, Japan)
weighing 16–21 g were used. All of the animal experi-
ments were performed in a humanemanner after receiving
approval from the Institutional Animal Experiment Com-
mittee of the University of Tsukuba. The animal experi-
ments were performed in accordance with the
Regulations for Animal Experiments at our university and
the Fundamental Guidelines for the Proper Conduct of
Animal Experiments and Related Activities in Academic
Research Institutions under the jurisdiction of the Ministry
of Education, Culture, Sports, Science and Technology
of Japan.
Drug delivery system and ﬂuorescent staining assay
Multifunctional envelope-type nano devices were devel-
oped for use as an siRNADDS at the Laboratory of Innova-
tive Nanomedicine, Faculty of Pharmaceutical Sciences,
Hokkaido University.17,18 We have developed two types
of MEND: the ﬁrst is a nonselective MEND, which mainly
targets hepatocytes;19,20 the second is an LSEC-transfer efﬁ-
cient MEND, which targets LSEC more efﬁciently than
nonselective MEND.13,14 Four- to ﬁve-week-old female
ICR mice (Japan SLC, Shizuoka, Japan) received an i.v.
injection of rhodamine-DOPE-labeled nonselectiveMEND
or LSEC-transfer efﬁcient MEND, and the mice were killed
25 min after treatment. The portal vein was cut, a needle
was introduced into the vena cava, and 10–15 mL of a
heparin-containing (40 units/mL) PBS solution was used
to remove the remaining blood and cell surface-bound
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MEND in the liver. The liver was then excised, washed with
saline and sliced into 10–15-mm blocks with scissors. The
liver sections were incubatedwith a 20-fold volume of a di-
luted solution of Hoechst 33342 (1 mg/mL) and isolectin
B4 in HEPES buffer for 1 h. The specimens were placed
on a 35-mm glass base dish (Iwaki, Osaka, Japan) and ob-
served using confocal laser scanning microscopy (A1 Con-
focal Laser Microscope System, Nikon Instruments, Tokyo,
Japan).21 We encapsulated Bax siRNA into the nonselective
MEND and the LSEC-transfer efﬁcient MEND. Each puri-
ﬁedMEND formulation was stored at 4°C and usedwithin
2 weeks.
siRNA transfection and Jo2 application
The Fas/Fas ligand system plays important roles in hepatitis
and other liver diseases.22,23 As a model of acute liver dam-
age, we have administrated the anti-Fas antibody inmice.12
Micewere anesthetizedwith isoﬂurane.Onemicrogramper
gram of bodyweight of siRNA was diluted to 150 μL with
saline and injected via the tail vein.24,25 Twenty-four hours
after siRNA administration, 0.2 mg/kg bodyweight of anti-
Fas antibody was injected i.p. to induce acute liver failure.
The mice were divided into three groups: (i) the control
group (n=7), in which mice were injected with saline only;
(ii) the nonselective group (n=7), in which siRNA was ad-
ministrated via the nonselective MEND; and (iii) the LSEC-
transfer efﬁcient group (n=7), in which the LSEC-transfer
efﬁcient MEND was used to deliver siRNA. At 0, 2, 6 and
24 h after the anti-Fas antibody treatment, blood samples
were collected and centrifuged for 10 min at 4°C at
1200 g. The supernatants were collected and stored at
80°C. The mice in each group were killed, and the livers
were removed and divided into three specimens: one sec-
tionwas ﬁxed in 10%buffered formalin for subsequent his-
tological analysis, silver impregnation and terminal
deoxynucleotidyl transferase dUTP nick end labeling
(TUNEL) staining; another was ﬁxed in 2% glutaraldehyde
for transmission electronmicroscopy analysis; and the third
was snap-frozen in liquid nitrogen and stored at 80°C
until use for real-time RT–PCR and western blot analysis.
Biochemical assays
To estimate the extent of liver injury, the serum level of
ALT was determined using an autoanalyzer (Fuji Dri-chem
7000 V; Fujiﬁlm, Tokyo, Japan).
Histological analysis
The liver specimens were stained with hematoxylin–eosin
(HE) and silver impregnation to observe liver damage,
and changes to the sinusoidal structure were examined
using standard histological techniques. To detect the sinu-
soidal changes, the relative ratio of the sinusoidal area
stained with silver impregnation around the portal vein
was calculated at ×400 magniﬁcation under a microscope
(BZ-9000, BZ Analysis Application; Keyence, Osaka,
Japan). Apoptosis in the liver tissue was detected by the
appearance of apoptotic cells in the TUNEL assay (In Situ
Apoptosis Detection Kit; Takara Bio, Otsu, Japan), and
the ratio of TUNEL positive/total hepatocytes was
calculated with a microscope at ×400 magniﬁcation.
Transmission electron microscopy
The liver tissues were removed 24 h after the anti-Fas anti-
body treatment and were cut into small pieces (~1 mm3).
The specimens were ﬁxed with 2% glutaraldehyde in
0.1 M phosphate buffer and then were dehydrated
through a graded series of ethanol, passed through pro-
pylene oxide and embedded in EPON 812. Ultra-thin
sections were mounted on copper grids and stained with
uranyl acetate and lead citrate before observation using
a Hitachi H-7000 transmission electron microscope
(Hitachi, Tokyo, Japan).
Total RNA extraction and quantitative RT–PCR
Frozen liver tissue samples were homogenized, and total
cellular RNA was isolated using a NucleoSpin RNA Kit
(Takara Bio, Otsu, Japan). The RNA concentrations were
determined by measuring the absorbance at 260/280 nm
with a NanoDrop Spectrophotometer (NanoDrop Tech-
nologies, Wilmington, DE, USA). Complimentary DNA
was synthesized using AMV Reverse Transcriptase
(Promega, Madison, WI, USA) and random primers
(Takara Bio). Brieﬂy, a mixture of 1 mM deoxyribonucleo-
tide triphosphate (Fermentas Life Sciences, Burlingame,
ON, Canada), 0.025 mg/mL random primer, 0.25 U/mL
reverse transcriptase and 500 ng of total RNA was incu-
bated at 30°C for 10 min, 37°C for 60 min and 95°C
for 5 min before storage at 80°C. RT–PCR primers were
designed using Primer Express Software for Real-Time
PCR version 3.0 (Applied Biosystems, Foster City, CA,
USA) with GenBank sequences. Primers were purchased
from Hokkaido System Science (Hokkaido, Japan). The
Bax (NM_007527) primer sequences were 5′-CAGGATG
CGTCCACCAAGA-3′ and 5′-CTGCCACCCGGAAGAAGAC-3′.
The Bak (NM_007523.2) primer sequences were
5′-GGAATGCCTACGAACTCTTCA-3′ and 5′-CCAGCTGA
TGCCACTCTTAAA-3′. The glyceraldehyde 3-phosphate de-
hydrogenase (NM_008084; endogenous control) primer
sequences were 5′-CCAGCCTCGTCCCGTAGA-3′ and 5′-
CGCCCAATACGGCCAAA-3′. RT–PCR was performed
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using SYBRGreen Real-time PCRMaster Mix-Plus (Toyobo,
Osaka, Japan) and an Applied Biosystems 7300 Real-time
PCR system (Applied Biosystems) following the procedure
recommended by the manufacturers.26,27
Protein extraction and western blot analysis
Frozen liver tissue samples were homogenized in a buffer
consisting of 150 mM/L NaCl, 50 mM Tris–HCl, 1% NP-
40 and proteinase inhibitors. The samples were centrifuged
and the supernatants were collected for analysis. The
samples were separated on 12% SDS polyacrylamide gel
electrophoresis gels and transferred to nitrocellulose mem-
branes (Millipore, Bedford, MA, USA). Anti-Bax (2772)
and anti-cleaved caspase-3 (9661) antibodies (Cell Signal-
ing, Beverly, MA, USA) were used as primary antibodies. A
secondary goat antirabbit antibody conjugated to horserad-
ish peroxidase was purchased from Zymed Laboratories
(San Francisco, CA, USA). Protein quantities were deter-
mined by densitometry (n=3 independent experiments).
Statistical analysis
Pairwise comparisons of subgroups were performed using
Student’s t-test. Comparisons betweenmultiple treatments
were performed using one-way ANOVA, followed by the
Bonferroni–Dunn multiple comparisons post-hoc test. In
all cases, P<0.05 was considered signiﬁcant.
RESULTS
Inhibition of Bax expression suppresses LSEC
apoptosis
THE EXPRESSION OF Bax mRNA in the Bax siRNA(+)group was signiﬁcantly lower than that in the Bax
siRNA() group at 0, 12 and 24 h after administration of
the anti-Fas antibody (Fig. 1a) and at 0, 2, 4 h after STS
treatment (Fig. 1b). Bax and cleaved caspase-3 protein ex-
pression was signiﬁcantly suppressed in the Bax siRNA(+)
group compared with the Bax siRNA() group at 12 and
24 h after administration of the anti-Fas antibody (Fig. 1c)
and at 2 and 4 h after STS treatment (Fig. 1d).
Novel MEND aggregates in liver sinusoid
The rhodamine-DOPE-labeled MEND signal overlapped
with the isolectin B4-stained hepatic sinusoid, indicating
that the MEND accumulated in the liver sinusoid. The pat-
tern of accumulation of the LSEC-transfer efﬁcient MEND
indicated that this MEND had greater efﬁcacy than the
nonselective MEND toward LSECs (Fig. 2).
Figure 1 In vitro quantitative reverse transcription polymerase chain reaction (RT–PCR) and western blot analyses. (a,b) The expression
of Bax mRNA was measured by real-time RT–PCR after administration of (a) the anti-Fas antibody and (b) staurosporine (STS) (n=3
each group). (c,d) Representative immunoblots and densitometry analysis of Bax and cleaved caspase-3 protein expression after
administration of (c) the anti-Fas antibody and (d) STS; β-actin served as the loading control (n= 3 independent experiments).
Mean± standard deviation. *P< 0.05 versus the Bax siRNA() group. GAPDH, glyceraldehyde 3-phosphate dehydrogenase.
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Inhibition of Bax in LSECs reduces liver damage
All mice survived at 24 h after the administration of an
anti-Fas antibody. Serum ALT was signiﬁcantly lower in
the LSEC-transfer efﬁcient group than in the control and
nonselective groups at 6 and 24 h after administration of
the anti-Fas antibody (Fig. 3a). At 48 h after administration
of the anti-Fas antibody, serum ALT recovered to almost
normal, 51±29 IU/L (mean± standard deviation; n=4,
data not shown).
Light microscopy photographs of the HE-stained liver
tissues 24 h after administration of the anti-Fas antibody
are shown in Figure 3(b). There was less accumulation of
inﬂammatory cells and less disruption of the sinusoidal
structure in the LSEC-transfer efﬁcient group compared
with the other groups. Necrotic changes were unclear in
all of the groups.
Protecting LSECs results in a decrease in
hepatocyte apoptosis
Bax mRNA expression in the nonselective and LSEC-
transfer efﬁcient groups was signiﬁcantly lower than that
in the control group 24 h after administration of the
anti-Fas antibody (Fig. 4a). Bax protein expression in the
nonselective and LSEC-transfer efﬁcient groups was sup-
pressed compared with that in the control group 24 h after
administration of the anti-Fas antibody (Fig. 4b). Cleaved
caspase-3 protein expression was signiﬁcantly lower in
the LSEC-transfer efﬁcient group compared with the other
groups (Fig. 4b). BakmRNA expression in the nonselective
group and LSEC-transfer efﬁcient groups was lower than
that of the control group, though these differences were
not signiﬁcant (Fig. 4a).
Figure 2 Accumulation of each multifunctional envelope-type
nano device (MEND). Accumulation of the nonselective MEND
and the liver sinusoidal endothelial cell (LSEC)-transfer efﬁcient
MEND in vivo. The green and red colors represent isolectin
B4 staining of the hepatic sinusoid and the rhodamine-
DOPE-labeled MEND, respectively. Scale bars, 50 μm.
Figure 3 Liver enzymes in vivo and hema-
toxylin–eosin (HE) staining of liver tissues.
(a) Changes in serum alanine aminotrans-
ferase (ALT) in the control, nonselective
and liver sinusoidal endothelial cell
(LSEC)-transfer efﬁcient groups at 0, 2, 6
and 24 h after anti-Fas antibody treatment
(n=7 each group). Mean± standard devia-
tion. *P< 0.05 versus the other groups. (b)
Light microscopy images of HE-stained
liver tissues 24 h after anti-Fas antibody
treatment (original magniﬁcation ×200).
Scale bars, 100 μm.
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There were fewer TUNEL positive hepatocytes in the
LSEC-transfer efﬁcient group than in the control and
nonselective groups (Fig. 4c). The ratio of TUNEL
positive/total hepatocytes in the LSEC-transfer efﬁcient
group was signiﬁcantly lower than that in the other groups
(Fig. 4d).
Suppressing LSEC apoptosis maintains the
sinusoidal structure
At 24 h after anti-Fas antibody treatment, the silver-stained
sinusoidal structures were better maintained in the LSEC-
transfer efﬁcient group compared with the other groups
(Fig. 5a). The relative ratio of silver-stained sinusoidal
structure around the portal vein was signiﬁcantly higher
in the LSEC-transfer efﬁcient group compared with the
other groups (Fig. 5b).
The transmission electron microscopy images of the
sinusoidal structure 24 h after anti-Fas antibody administra-
tion are shown in Figure 5(c). In the control and
nonselective groups, the sinusoidal endothelial lining was
destroyed anddetached into the sinusoidal space, andDisse’s
spaces were enlarged. In contrast, the sinusoidal endothelial
lining was preserved in the LSEC-transfer efﬁcient group.
DISCUSSION
HEPATOCYTE APOPTOSIS IS the main cause of acuteliver failure, and LSEC apoptosis occurs during acute
liver failure.1,2,4,28–32 It is necessary to elucidate the
Figure 4 In vivo quantitative reverse transcription polymerase chain reaction (RT–PCR), western blot and terminal deoxynucleotidyl
transferase dUTP nick end labeling (TUNEL) assay of liver tissues. (a) Bax and Bak mRNA expression in liver tissues was measured by
real-time RT–PCR 24 h after anti-Fas antibody administration (n=7 each group). (b) Representative immunoblots and densitometry
analysis of Bax and cleaved caspase-3 protein expression 24 h after anti-Fas antibody treatment; β-actin served as the loading control
(n =3 independent experiments) (right). (c) TUNEL assay of liver tissues 24 h after administration of the anti-Fas antibody (original
magniﬁcation ×200). Scale bars, 100 μm. (d) Ratio of TUNEL positive/total hepatocytes (n =7 each group). Mean± standard deviation.
*P< 0.05 versus the other groups. LSEC, liver sinusoidal endothelial cell.
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pathogenic mechanism by which apoptosis occurs in he-
patocytes and LSECs to prevent apoptosis-induced acute
liver failure. However, the precise apoptotic mechanism
has not been clariﬁed due to the lack of a suitable
method for suppressing apoptosis in particular cells of
the liver, speciﬁcally in hepatocytes and LSECs. Previ-
ously, we demonstrated that LSECs are impaired before
hepatocyte injury in acute liver failure.12 Moreover,
LSECs play protective roles during inﬂammation and tox-
icity.33,34 Therefore, we hypothesized that LSEC apopto-
sis prior to hepatocyte apoptosis is strongly associated
with acute liver damage. To evaluate this hypothesis, we
investigated the efﬁcient suppression of LSEC apoptosis
using a novel DDS, namely, a MEND, in a mouse model
of acute liver failure. Compared with the nonselective
suppression of liver apoptosis, the efﬁcient suppression
of LSEC apoptosis decreased the amount of acute liver
damage. The present study also revealed that maintaining
the hepatic sinusoidal structure by suppressing LSEC ap-
optosis diminished acute liver injury.
Bax, a pro-apoptotic factor in themitochondrial apopto-
sis pathway, is expressed in the liver and promotes liver
apoptosis.10,11 The siRNA-mediated inhibition of Bax
suppresses hepatocyte apoptosis in vitro.9,35 Bax is also
expressed in LSECs, and the inhibition of Bax has been
suggested to suppress LSEC apoptosis.32,36 However, the
function of Bax in LSECs is unknown. The present study
clearly indicated that inhibiting Bax in LSECs also has an
anti-apoptotic effect in vitro.
In an animal model of acute liver failure, the siRNA-
mediated inhibition of Bax suppresses hepatocyte and
liver damage.8,9 However, it was unclear whether Bax in
LSECs, as opposed to in hepatocytes, has a signiﬁcant ef-
fect on acute liver failure. We previously developed a
MEND that is covered with a lipid envelope membrane
as a novel DDS for siRNA.17,18 Various modiﬁcations to
this MEND can be implemented to speciﬁcally deliver
the device to target cells within organs.18,37–40 We previ-
ously developed a MEND that accumulates in the liver
and is incorporated mainly into hepatocytes.19,20 How-
ever, this MEND is nonselective and targets both hepato-
cytes and LSECs.13,14 A novel MEND was developed to
inhibit Bax expression and suppress apoptosis in LSECs
more efﬁciently than nonselective MEND.13,41 We previ-
ously reported that the LSEC-transfer efﬁcacy of the novel
MEND is higher than that of the nonselective MEND.13,14
In this study, a ﬂuorescent staining assay indicated greater
accumulation of the novel MEND compared with the
nonselective MEND in the sinusoidal structure. Moreover,
compared with the nonselective MEND, the novel MEND
can encapsulate siRNA to signiﬁcantly suppress the expres-
sion of a speciﬁc gene (Tie2) in LSECs.14 Based on the
Figure 5 Silver impregnation assay of liver tissues and transmission electron microscopy of liver tissues. (a) Silver staining of liver
tissues 24 h after administration of the anti-Fas antibody (original magniﬁcation ×200). Scale bars, 100 μm. (b) Relative ratio of the
silver-stained sinusoidal area around the portal vein (n= 7 each group). Mean± standard deviation. *P< 0.05 versus the other groups.
(c) Transmission electron microscopy of liver tissues 24 h after anti-Fas antibody administration (×6000). Scale bars, 1 μm. LSEC, liver
sinusoidal endothelial cell.
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results of the current study, the LSEC-transfer efﬁcient
MEND is effective as a DDS for Bax siRNA to suppress
LSEC apoptosis.
The results of this study indicate that the LSEC-transfer
efﬁcientMEND,which suppresses LSEC apoptosis, reduces
hepatocyte apoptosis and acute liver damage. Acute liver
damage decreases after protecting against or inhibiting
LSEC apoptosis.42,43 LSECs are located between the blood
and hepatocytes and play an important role in the stability
of hepatocytes.33 Disruptions in the sinusoidal structure
caused by LSEC injury elicit hemorrhage-induced bio-
chemical events and disturb the sinusoidal continuity,
leading to secondary hepatocyte damage during acute liver
failure.30,44 In addition, the deterioration of hepaticmicro-
circulation induced by LSEC damage leads to hepatocyte
injury.45–48 The electron microscopy ﬁndings of the pres-
ent study revealed that only the efﬁcient suppression of
LSEC apoptosis prevented LSEC disturbances and main-
tained the morphologies of the sinusoidal structures and
Disse’s space. We elucidated the importance of efﬁciently
suppressing LSEC apoptosis for maintaining sinusoidal
structure. Therefore, the prevention of LSEC apoptosis
should become a target for treating acute liver failure.
In this study, despite the administration of a
nonselective MEND to inhibit Bax in hepatocytes, it was
impossible to suppress liver damage. Hikita et al. reported
that the suppression of acute liver damage induced by a
large amount of anti-Fas antibody was insufﬁcient in mice
with Bax-deﬁcient hepatocytes.36 This result is likely asso-
ciated with the fact that inhibiting Bax in LSECs, not just
hepatocytes, is important for the siRNA-mediated treat-
ment of acute liver failure. Suppressing apoptosis in the
entire liver via i.v. siRNA administration was reported to
decrease acute liver damage, but this suppression effect
was due to the administration of approximately threefold
the amount of siRNA as was used in the present study.6,7,9
In this study, the dose of Bax siRNA delivered via a
nonselective MEND was considered too low to cover the
therapeutic range for protecting against LSEC damage.
However, the LSEC-transfer efﬁcient MEND enabled the
effective reduction of LSEC damage using only a small
amount of Bax siRNA. As mentioned above, the novel
MEND may be an effective DDS for clinical applications
in the treatment of acute liver failure. However, the effect
duration, amount of accumulation, and side-effects on
other organs of both the siRNA and MENDmust be inves-
tigated prior to their clinical application.
Bax siRNA sealed in each MENDmay be assumed to be
action of non-parenchymal cells other than LSECs. Bax ex-
pression of non-parenchymal cells in the nonselective and
LSEC-transfer efﬁcient groups was predicted to be
inhibited almost equally. Thismay be explained by the fact
that non-parenchymal cells contain many Kupffer cells
and hepatic stellate cells in addition to LSECs.49 However,
we did not describe the effect of Bax siRNA sealed in each
MEND on non-parenchymal cells in the present study. It
was not expected to separate LSECs fromnon-parenchymal
cells with sustaining the efﬁcacy of Bax siRNA.50 Further in-
vestigations are needed to support our results of Bax inhibi-
tion in LSECs.
In conclusion, suppressing LSEC apoptosis via the efﬁ-
cient inhibition of Bax in LSECs maintains the sinusoidal
structure, thereby reducing hepatocyte apoptosis and liver
damage during acute liver failure. In clinical settings, there
is no effective treatment for acute liver failure other than
liver transplantation. Protecting LSECs and the sinusoidal
structure withMEND could be clinically useful for treating
acute liver failure.
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